Vext Science（VV5）株式概要ベクストサイエンス社は、その子会社を通じて、米国の大麻産業において総合的な農業技術、サービス、不動産管理サービスを提供している。 詳細VV5 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長4/6過去の実績0/6財務の健全性2/6配当金0/6報酬当社が推定した公正価値より96.7%で取引されている 収益は年間112.79%増加すると予測されています リスク分析German市場と比較した過去 3 か月間の株価の変動意味のある時価総額がありません ( €41M )すべてのリスクチェックを見るVV5 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.1780.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-19m101m2016201920222025202620282031Revenue US$101.1mEarnings US$14.9mAdvancedSet Fair ValueView all narrativesVext Science, Inc. 競合他社Cantourage GroupSymbol: XTRA:HIGHMarket cap: €75.6mBiofronteraSymbol: XTRA:B8FKMarket cap: €14.7mTFF PharmaceuticalsSymbol: MUN:0K30Market cap: €9.7mPEPTONIC medicalSymbol: DB:28LMarket cap: €560.2m価格と性能株価の高値、安値、推移の概要Vext Science過去の株価現在の株価CA$0.1752週高値CA$0.2252週安値CA$0.064ベータ0.771ヶ月の変化1.83%3ヶ月変化13.61%1年変化142.03%3年間の変化-5.11%5年間の変化-71.69%IPOからの変化-86.03%最新ニュースお知らせ • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026お知らせ • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026お知らせ • Nov 11Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025お知らせ • Oct 13Vext Science, Inc., Annual General Meeting, Dec 11, 2025Vext Science, Inc., Annual General Meeting, Dec 11, 2025.お知らせ • Aug 11Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025お知らせ • May 13Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025最新情報をもっと見るRecent updatesお知らせ • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026お知らせ • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026お知らせ • Nov 11Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025お知らせ • Oct 13Vext Science, Inc., Annual General Meeting, Dec 11, 2025Vext Science, Inc., Annual General Meeting, Dec 11, 2025.お知らせ • Aug 11Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025お知らせ • May 13Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025お知らせ • Apr 01Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC.Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025. Vext Science utilize a non-cash consideration in the transaction. For the period end date December 31, 2024, Vapen Kentucky, LLC reported $46.3 million revenue and $3.3 million net assets based on the equity accounted investment of Vext Science. Vext Science, Inc. (CNSX:VEXT) completed the acquisition of the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025.お知らせ • Mar 20Vext Science, Inc. to Report Q4, 2024 Results on Mar 31, 2025Vext Science, Inc. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2025お知らせ • Nov 07Vext Science, Inc. to Report Q3, 2024 Results on Nov 21, 2024Vext Science, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 21, 2024お知らせ • Oct 15Vext Science, Inc., Annual General Meeting, Dec 13, 2024Vext Science, Inc., Annual General Meeting, Dec 13, 2024.Reported Earnings • Aug 21Second quarter 2024 earnings released: US$0.018 loss per share (vs US$0.004 profit in 2Q 2023)Second quarter 2024 results: US$0.018 loss per share (down from US$0.004 profit in 2Q 2023). Revenue: US$8.43m (down 8.3% from 2Q 2023). Net loss: US$4.39m (down US$4.93m from profit in 2Q 2023). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.お知らせ • Aug 09Vext Science, Inc. to Report Q2, 2024 Results on Aug 20, 2024Vext Science, Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 20, 2024お知らせ • May 26Vext Science, Inc. to Report Q1, 2024 Results on May 29, 2024Vext Science, Inc. announced that they will report Q1, 2024 results Pre-Market on May 29, 2024Reported Earnings • May 13Full year 2023 earnings released: EPS: US$0.027 (vs US$0.079 in FY 2022)Full year 2023 results: EPS: US$0.027 (down from US$0.079 in FY 2022). Revenue: US$34.8m (down 1.7% from FY 2022). Net income: US$4.40m (down 60% from FY 2022). Profit margin: 13% (down from 31% in FY 2022). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.お知らせ • Apr 16Vext Science, Inc. to Report Q4, 2023 Results on Apr 25, 2024Vext Science, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024New Risk • Mar 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€46.5m market cap, or US$50.7m).New Risk • Feb 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (46% increase in shares outstanding). Market cap is less than US$100m (€53.3m market cap, or US$57.4m).お知らせ • Jan 17Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive RoleVext Science, Inc. announced that Jason Thai Nguyen has transitioned out of his executive positions with the Company, including resigning from all positions with the Company's subsidiaries and affiliates. Mr. Nguyen will continue to serve the Company through his position as a director of the Company and Chairman of the board of directors.Reported Earnings • Nov 29Third quarter 2023 earnings released: US$0.012 loss per share (vs US$0.003 profit in 3Q 2022)Third quarter 2023 results: US$0.012 loss per share (down from US$0.003 profit in 3Q 2022). Revenue: US$8.10m (up 5.6% from 3Q 2022). Net loss: US$1.84m (down US$2.26m from profit in 3Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.お知らせ • Nov 22Vext Science, Inc. to Report Q3, 2023 Results on Nov 28, 2023Vext Science, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 28, 2023お知らせ • Oct 14Vext Science, Inc., Annual General Meeting, Dec 15, 2023Vext Science, Inc., Annual General Meeting, Dec 15, 2023.New Risk • Oct 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 57% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€39.4m market cap, or US$41.4m).お知らせ • Oct 13Vext Science, Inc. announced that it has received $11.5 million in funding from LLF Financial S.A.On October 12, 2023, Vext Science, Inc. closed the transaction. The company has now issued 67,647,058 common shares at a price of $0.17 per share for the gross proceeds of $11,500,000. In connection with the offering, the company has paid a cash finder's fee to certain registered dealers consisting of approximately $3,285. The transaction included participation from Mark Opzoomer, Trevor Smith and Sopica Special Opportunities Fund Limited managed by LLF Financial S.A. for 42,798,529 shares. Sopica Special Opportunities Fund Limited purchased 41,176,470 subordinate voting shares for $7,000,000 and its stake is increased by 21.56% (from 13.00% to 34.56%) on a non-diluted basis. Immediately prior to the Private Placement, the Acquirors beneficially owned or otherwise exercised control or direction over 10,726,849 Subordinate Voting Shares, 4,303,182 warrants to purchase Subordinate Voting Shares and 112,486 Class A common shares, representing approximately 26.79% of the issued and outstanding Subordinate Voting Shares. As a result of the Private Placement, the Acquirors beneficially own or otherwise exercise control or direction over 51,903,319 Subordinate Voting Shares, 4,303,182 Warrants and 112,486 Multiple Voting Shares, representing approximately 40.70% of the issued and outstanding Subordinate Voting Shares as at October 12, 2023.Reported Earnings • Aug 23Second quarter 2023 earnings released: EPS: US$0.004 (vs US$0.014 in 2Q 2022)Second quarter 2023 results: EPS: US$0.004 (down from US$0.014 in 2Q 2022). Revenue: US$9.19m (up 4.8% from 2Q 2022). Net income: US$535.5k (down 73% from 2Q 2022). Profit margin: 5.8% (down from 22% in 2Q 2022). Revenue is forecast to grow 42% p.a. on average during the next 2 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.お知らせ • Aug 18Vext Science, Inc. to Report Q2, 2023 Results on Aug 23, 2023Vext Science, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 23, 2023お知らせ • Aug 11+ 1 more updateVext Science, Inc. Resigns Stephan Bankosz as Corporate Secretary, Effective August 25, 2023Vext Science, Inc. reported that Stephan Bankosz has resigned as CFO and Corporate Secretary of the Company effective August 25, 2023 to pursue other opportunities. Vext will appoint experienced financial executive and operator Trevor Smith as CFO. In the coming weeks Mr. Bankosz will assist with the transition of duties to Mr. Smith, which is expected to be completed after Vext has reported its second quarter 2023 earnings. Nalee Pham, the Company's Chief of Staff and a director of the Company's wholly-owned operating subsidiary Herbal Wellness Center, LLC has been appointed Corporate Secretary.Reported Earnings • May 26First quarter 2023 earnings released: EPS: US$0 (vs US$0.016 in 1Q 2022)First quarter 2023 results: EPS: US$0 (down from US$0.016 in 1Q 2022). Revenue: US$9.11m (down 16% from 1Q 2022). Net income: US$73.1k (down 97% from 1Q 2022). Profit margin: 0.8% (down from 21% in 1Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.お知らせ • May 16Vext Science, Inc. to Report Q1, 2023 Results on May 25, 2023Vext Science, Inc. announced that they will report Q1, 2023 results Pre-Market on May 25, 2023Reported Earnings • Mar 23Full year 2022 earnings released: EPS: US$0.079 (vs US$0.036 in FY 2021)Full year 2022 results: EPS: US$0.079 (up from US$0.036 in FY 2021). Revenue: US$35.4m (down 4.9% from FY 2021). Net income: US$10.9m (up 119% from FY 2021). Profit margin: 31% (up from 13% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Board Change • Dec 22Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mark Opzoomer was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.007 in 3Q 2021)Third quarter 2022 results: EPS: US$0.003 (down from US$0.007 in 3Q 2021). Revenue: US$7.67m (down 18% from 3Q 2021). Net income: US$423.5k (down 56% from 3Q 2021). Profit margin: 5.5% (down from 10% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.013 in 2Q 2021)Second quarter 2022 results: EPS: US$0.014 (up from US$0.013 in 2Q 2021). Revenue: US$8.77m (down 6.5% from 2Q 2021). Net income: US$1.95m (up 8.9% from 2Q 2021). Profit margin: 22% (up from 19% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 19%, compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 02First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: US$10.8m (up 18% from 1Q 2021). Net income: US$3.46m (up 204% from 1Q 2021). Profit margin: 32% (up from 12% in 1Q 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 21%, compared to a 6.9% growth forecast for the industry in Germany.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Apr 22Full year 2021 earnings released: EPS: US$0.036 (vs US$0.023 in FY 2020)Full year 2021 results: EPS: US$0.036 (up from US$0.023 in FY 2020). Revenue: US$37.2m (up 48% from FY 2020). Net income: US$4.99m (up 135% from FY 2020). Profit margin: 13% (up from 8.4% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 7.7% growth forecast for the pharmaceuticals industry in Germany.Board Change • Feb 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 19Third quarter 2021 earnings releasedThe company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: US$9.40m (up 18% from 3Q 2020). Net income: US$970.1k (down 31% from 3Q 2020). Profit margin: 10% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.Reported Earnings • Aug 25Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$9.38m (up 39% from 2Q 2020). Net income: US$1.79m (up 222% from 2Q 2020). Profit margin: 19% (up from 8.3% in 2Q 2020). The increase in margin was driven by higher revenue.Reported Earnings • May 29First quarter 2021 earnings released: EPS US$0.011 (vs US$0.012 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$9.16m (up 124% from 1Q 2020). Net income: US$1.14m (up US$2.11m from 1Q 2020). Profit margin: 12% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue.Reported Earnings • Apr 17Full year 2020 earnings releasedThe company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: US$25.2m (up 13% from FY 2019). Net income: US$2.13m (down 24% from FY 2019). Profit margin: 8.4% (down from 13% in FY 2019). The decrease in margin was driven by higher expenses.Is New 90 Day High Low • Dec 30New 90-day high: €0.66The company is up 141% from its price of €0.27 on 01 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.Reported Earnings • Nov 29Third quarter 2020 earnings released: EPS US$0.017The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$7.95m (up 43% from 3Q 2019). Net income: US$1.41m (up 80% from 3Q 2019). Profit margin: 18% (up from 14% in 3Q 2019). The increase in margin was driven by higher revenue.Is New 90 Day High Low • Nov 29New 90-day high: €0.36The company is up 22% from its price of €0.30 on 31 August 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.Is New 90 Day High Low • Oct 10New 90-day low: €0.24The company is down 21% from its price of €0.30 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period.Is New 90 Day High Low • Sep 23New 90-day low: €0.26The company is down 18% from its price of €0.32 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period.株主還元VV5DE PharmaceuticalsDE 市場7D-5.6%5.7%2.4%1Y142.0%25.9%1.2%株主還元を見る業界別リターン: VV5過去 1 年間で25.9 % の収益を上げたGerman Pharmaceuticals業界を上回りました。リターン対市場: VV5過去 1 年間で1.2 % の収益を上げたGerman市場を上回りました。価格変動Is VV5's price volatile compared to industry and market?VV5 volatilityVV5 Average Weekly Movement10.8%Pharmaceuticals Industry Average Movement6.4%Market Average Movement6.1%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.7%安定した株価: VV5の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: VV5の weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2015n/aEric Offenbergerwww.vextscience.comベクストサイエンス社は、その子会社を通じて、米国の大麻産業において総合的な農業技術、サービス、不動産管理サービスを提供している。同社は栽培施設、製造ユニット、調剤薬局を所有・管理し、THCとCBDのカートリッジ、濃縮液、エディブルの栽培、抽出、製造、販売に携わっている。同社はまた、小売調剤薬局活動や、Vapen、Pure Touch、Appalachian Pharm、Herbal Wellness、Revibeブランドの大麻THCおよびヘンプCBD製品の卸売販売も行っている。さらに、運営契約や直接販売を通じて、大麻分野の事業体に経営、助言、栽培、非大麻製品、薬局サービスを提供している。同社は以前、Vapen MJ Ventures Corporationとして知られていたが、2019年11月にVext Science, Inc.に社名を変更した。Vext Science, Inc.は2015年に法人化され、アリゾナ州フェニックスに本社を置いている。もっと見るVext Science, Inc. 基礎のまとめVext Science の収益と売上を時価総額と比較するとどうか。VV5 基礎統計学時価総額€40.71m収益（TTM）-€13.40m売上高(TTM)€44.77m0.9xP/Sレシオ-3.0xPER（株価収益率VV5 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計VV5 損益計算書（TTM）収益US$51.97m売上原価US$34.27m売上総利益US$17.70mその他の費用US$33.25m収益-US$15.55m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.062グロス・マージン34.06%純利益率-29.93%有利子負債／自己資本比率55.3%VV5 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 13:03終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vext Science, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Matt BottomleyCanaccord GenuityShaan MirCanaccord GenuityNeal GilmerHaywood Securities Inc.4 その他のアナリストを表示
お知らせ • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026
お知らせ • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026
お知らせ • Nov 11Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025
お知らせ • Oct 13Vext Science, Inc., Annual General Meeting, Dec 11, 2025Vext Science, Inc., Annual General Meeting, Dec 11, 2025.
お知らせ • Aug 11Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025
お知らせ • May 13Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025
お知らせ • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026
お知らせ • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026
お知らせ • Nov 11Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025
お知らせ • Oct 13Vext Science, Inc., Annual General Meeting, Dec 11, 2025Vext Science, Inc., Annual General Meeting, Dec 11, 2025.
お知らせ • Aug 11Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025
お知らせ • May 13Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025
お知らせ • Apr 01Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC.Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025. Vext Science utilize a non-cash consideration in the transaction. For the period end date December 31, 2024, Vapen Kentucky, LLC reported $46.3 million revenue and $3.3 million net assets based on the equity accounted investment of Vext Science. Vext Science, Inc. (CNSX:VEXT) completed the acquisition of the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025.
お知らせ • Mar 20Vext Science, Inc. to Report Q4, 2024 Results on Mar 31, 2025Vext Science, Inc. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2025
お知らせ • Nov 07Vext Science, Inc. to Report Q3, 2024 Results on Nov 21, 2024Vext Science, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 21, 2024
お知らせ • Oct 15Vext Science, Inc., Annual General Meeting, Dec 13, 2024Vext Science, Inc., Annual General Meeting, Dec 13, 2024.
Reported Earnings • Aug 21Second quarter 2024 earnings released: US$0.018 loss per share (vs US$0.004 profit in 2Q 2023)Second quarter 2024 results: US$0.018 loss per share (down from US$0.004 profit in 2Q 2023). Revenue: US$8.43m (down 8.3% from 2Q 2023). Net loss: US$4.39m (down US$4.93m from profit in 2Q 2023). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 09Vext Science, Inc. to Report Q2, 2024 Results on Aug 20, 2024Vext Science, Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 20, 2024
お知らせ • May 26Vext Science, Inc. to Report Q1, 2024 Results on May 29, 2024Vext Science, Inc. announced that they will report Q1, 2024 results Pre-Market on May 29, 2024
Reported Earnings • May 13Full year 2023 earnings released: EPS: US$0.027 (vs US$0.079 in FY 2022)Full year 2023 results: EPS: US$0.027 (down from US$0.079 in FY 2022). Revenue: US$34.8m (down 1.7% from FY 2022). Net income: US$4.40m (down 60% from FY 2022). Profit margin: 13% (down from 31% in FY 2022). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
お知らせ • Apr 16Vext Science, Inc. to Report Q4, 2023 Results on Apr 25, 2024Vext Science, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024
New Risk • Mar 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€46.5m market cap, or US$50.7m).
New Risk • Feb 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (46% increase in shares outstanding). Market cap is less than US$100m (€53.3m market cap, or US$57.4m).
お知らせ • Jan 17Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive RoleVext Science, Inc. announced that Jason Thai Nguyen has transitioned out of his executive positions with the Company, including resigning from all positions with the Company's subsidiaries and affiliates. Mr. Nguyen will continue to serve the Company through his position as a director of the Company and Chairman of the board of directors.
Reported Earnings • Nov 29Third quarter 2023 earnings released: US$0.012 loss per share (vs US$0.003 profit in 3Q 2022)Third quarter 2023 results: US$0.012 loss per share (down from US$0.003 profit in 3Q 2022). Revenue: US$8.10m (up 5.6% from 3Q 2022). Net loss: US$1.84m (down US$2.26m from profit in 3Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
お知らせ • Nov 22Vext Science, Inc. to Report Q3, 2023 Results on Nov 28, 2023Vext Science, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 28, 2023
お知らせ • Oct 14Vext Science, Inc., Annual General Meeting, Dec 15, 2023Vext Science, Inc., Annual General Meeting, Dec 15, 2023.
New Risk • Oct 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 57% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€39.4m market cap, or US$41.4m).
お知らせ • Oct 13Vext Science, Inc. announced that it has received $11.5 million in funding from LLF Financial S.A.On October 12, 2023, Vext Science, Inc. closed the transaction. The company has now issued 67,647,058 common shares at a price of $0.17 per share for the gross proceeds of $11,500,000. In connection with the offering, the company has paid a cash finder's fee to certain registered dealers consisting of approximately $3,285. The transaction included participation from Mark Opzoomer, Trevor Smith and Sopica Special Opportunities Fund Limited managed by LLF Financial S.A. for 42,798,529 shares. Sopica Special Opportunities Fund Limited purchased 41,176,470 subordinate voting shares for $7,000,000 and its stake is increased by 21.56% (from 13.00% to 34.56%) on a non-diluted basis. Immediately prior to the Private Placement, the Acquirors beneficially owned or otherwise exercised control or direction over 10,726,849 Subordinate Voting Shares, 4,303,182 warrants to purchase Subordinate Voting Shares and 112,486 Class A common shares, representing approximately 26.79% of the issued and outstanding Subordinate Voting Shares. As a result of the Private Placement, the Acquirors beneficially own or otherwise exercise control or direction over 51,903,319 Subordinate Voting Shares, 4,303,182 Warrants and 112,486 Multiple Voting Shares, representing approximately 40.70% of the issued and outstanding Subordinate Voting Shares as at October 12, 2023.
Reported Earnings • Aug 23Second quarter 2023 earnings released: EPS: US$0.004 (vs US$0.014 in 2Q 2022)Second quarter 2023 results: EPS: US$0.004 (down from US$0.014 in 2Q 2022). Revenue: US$9.19m (up 4.8% from 2Q 2022). Net income: US$535.5k (down 73% from 2Q 2022). Profit margin: 5.8% (down from 22% in 2Q 2022). Revenue is forecast to grow 42% p.a. on average during the next 2 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
お知らせ • Aug 18Vext Science, Inc. to Report Q2, 2023 Results on Aug 23, 2023Vext Science, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 23, 2023
お知らせ • Aug 11+ 1 more updateVext Science, Inc. Resigns Stephan Bankosz as Corporate Secretary, Effective August 25, 2023Vext Science, Inc. reported that Stephan Bankosz has resigned as CFO and Corporate Secretary of the Company effective August 25, 2023 to pursue other opportunities. Vext will appoint experienced financial executive and operator Trevor Smith as CFO. In the coming weeks Mr. Bankosz will assist with the transition of duties to Mr. Smith, which is expected to be completed after Vext has reported its second quarter 2023 earnings. Nalee Pham, the Company's Chief of Staff and a director of the Company's wholly-owned operating subsidiary Herbal Wellness Center, LLC has been appointed Corporate Secretary.
Reported Earnings • May 26First quarter 2023 earnings released: EPS: US$0 (vs US$0.016 in 1Q 2022)First quarter 2023 results: EPS: US$0 (down from US$0.016 in 1Q 2022). Revenue: US$9.11m (down 16% from 1Q 2022). Net income: US$73.1k (down 97% from 1Q 2022). Profit margin: 0.8% (down from 21% in 1Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
お知らせ • May 16Vext Science, Inc. to Report Q1, 2023 Results on May 25, 2023Vext Science, Inc. announced that they will report Q1, 2023 results Pre-Market on May 25, 2023
Reported Earnings • Mar 23Full year 2022 earnings released: EPS: US$0.079 (vs US$0.036 in FY 2021)Full year 2022 results: EPS: US$0.079 (up from US$0.036 in FY 2021). Revenue: US$35.4m (down 4.9% from FY 2021). Net income: US$10.9m (up 119% from FY 2021). Profit margin: 31% (up from 13% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Board Change • Dec 22Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mark Opzoomer was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.007 in 3Q 2021)Third quarter 2022 results: EPS: US$0.003 (down from US$0.007 in 3Q 2021). Revenue: US$7.67m (down 18% from 3Q 2021). Net income: US$423.5k (down 56% from 3Q 2021). Profit margin: 5.5% (down from 10% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.013 in 2Q 2021)Second quarter 2022 results: EPS: US$0.014 (up from US$0.013 in 2Q 2021). Revenue: US$8.77m (down 6.5% from 2Q 2021). Net income: US$1.95m (up 8.9% from 2Q 2021). Profit margin: 22% (up from 19% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 19%, compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 02First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: US$10.8m (up 18% from 1Q 2021). Net income: US$3.46m (up 204% from 1Q 2021). Profit margin: 32% (up from 12% in 1Q 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 21%, compared to a 6.9% growth forecast for the industry in Germany.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Apr 22Full year 2021 earnings released: EPS: US$0.036 (vs US$0.023 in FY 2020)Full year 2021 results: EPS: US$0.036 (up from US$0.023 in FY 2020). Revenue: US$37.2m (up 48% from FY 2020). Net income: US$4.99m (up 135% from FY 2020). Profit margin: 13% (up from 8.4% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 7.7% growth forecast for the pharmaceuticals industry in Germany.
Board Change • Feb 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 19Third quarter 2021 earnings releasedThe company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: US$9.40m (up 18% from 3Q 2020). Net income: US$970.1k (down 31% from 3Q 2020). Profit margin: 10% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.
Reported Earnings • Aug 25Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$9.38m (up 39% from 2Q 2020). Net income: US$1.79m (up 222% from 2Q 2020). Profit margin: 19% (up from 8.3% in 2Q 2020). The increase in margin was driven by higher revenue.
Reported Earnings • May 29First quarter 2021 earnings released: EPS US$0.011 (vs US$0.012 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$9.16m (up 124% from 1Q 2020). Net income: US$1.14m (up US$2.11m from 1Q 2020). Profit margin: 12% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue.
Reported Earnings • Apr 17Full year 2020 earnings releasedThe company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: US$25.2m (up 13% from FY 2019). Net income: US$2.13m (down 24% from FY 2019). Profit margin: 8.4% (down from 13% in FY 2019). The decrease in margin was driven by higher expenses.
Is New 90 Day High Low • Dec 30New 90-day high: €0.66The company is up 141% from its price of €0.27 on 01 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
Reported Earnings • Nov 29Third quarter 2020 earnings released: EPS US$0.017The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$7.95m (up 43% from 3Q 2019). Net income: US$1.41m (up 80% from 3Q 2019). Profit margin: 18% (up from 14% in 3Q 2019). The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Nov 29New 90-day high: €0.36The company is up 22% from its price of €0.30 on 31 August 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Oct 10New 90-day low: €0.24The company is down 21% from its price of €0.30 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period.
Is New 90 Day High Low • Sep 23New 90-day low: €0.26The company is down 18% from its price of €0.32 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period.
